Casey Woodring
Stock Analyst at JP Morgan
(0.81)
# 4,034
Out of 5,182 analysts
59
Total ratings
22.22%
Success rate
-10.78%
Average return
Main Sectors:
Stocks Rated by Casey Woodring
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRL Charles River Laboratories International | Maintains: Neutral | $165 → $160 | $171.23 | -6.56% | 11 | Apr 13, 2026 | |
| RVTY Revvity | Maintains: Neutral | $105 → $96 | $86.80 | +10.60% | 1 | Mar 31, 2026 | |
| TEM Tempus AI | Maintains: Neutral | $80 → $60 | $52.68 | +13.90% | 2 | Feb 25, 2026 | |
| GH Guardant Health | Maintains: Overweight | $120 → $130 | $88.50 | +46.89% | 3 | Feb 20, 2026 | |
| IQV IQVIA Holdings | Maintains: Overweight | $255 → $225 | $163.84 | +37.33% | 2 | Feb 6, 2026 | |
| ILMN Illumina | Maintains: Neutral | $130 → $120 | $128.52 | -6.63% | 3 | Feb 6, 2026 | |
| QGEN Qiagen | Maintains: Overweight | $55 → $60 | $38.09 | +57.52% | 5 | Feb 6, 2026 | |
| NTRA Natera | Maintains: Overweight | $250 → $260 | $204.39 | +27.21% | 3 | Dec 15, 2025 | |
| BRKR Bruker | Maintains: Overweight | $50 → $55 | $36.53 | +50.56% | 1 | Dec 15, 2025 | |
| BLLN BillionToOne | Maintains: Overweight | $150 → $145 | $81.76 | +77.35% | 2 | Dec 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $165 → $180 | $115.62 | +55.68% | 2 | Nov 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $26 → $22 | $12.29 | +79.01% | 5 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $15 | $22.28 | -32.68% | 1 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $16 | $15.81 | +1.20% | 3 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $14 → $12 | $7.97 | +50.56% | 1 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $300 → $325 | $299.79 | +8.41% | 1 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $600 → $650 | $468.04 | +38.88% | 1 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1,200 → $1,285 | $1,274.70 | +0.81% | 1 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $265 → $150 | $103.21 | +45.33% | 6 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $7 → $6 | $3.01 | +99.34% | 3 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $25 → $23 | $26.32 | -12.61% | 2 | Oct 31, 2023 |
Charles River Laboratories International
Apr 13, 2026
Maintains: Neutral
Price Target: $165 → $160
Current: $171.23
Upside: -6.56%
Revvity
Mar 31, 2026
Maintains: Neutral
Price Target: $105 → $96
Current: $86.80
Upside: +10.60%
Tempus AI
Feb 25, 2026
Maintains: Neutral
Price Target: $80 → $60
Current: $52.68
Upside: +13.90%
Guardant Health
Feb 20, 2026
Maintains: Overweight
Price Target: $120 → $130
Current: $88.50
Upside: +46.89%
IQVIA Holdings
Feb 6, 2026
Maintains: Overweight
Price Target: $255 → $225
Current: $163.84
Upside: +37.33%
Illumina
Feb 6, 2026
Maintains: Neutral
Price Target: $130 → $120
Current: $128.52
Upside: -6.63%
Qiagen
Feb 6, 2026
Maintains: Overweight
Price Target: $55 → $60
Current: $38.09
Upside: +57.52%
Natera
Dec 15, 2025
Maintains: Overweight
Price Target: $250 → $260
Current: $204.39
Upside: +27.21%
Bruker
Dec 15, 2025
Maintains: Overweight
Price Target: $50 → $55
Current: $36.53
Upside: +50.56%
BillionToOne
Dec 10, 2025
Maintains: Overweight
Price Target: $150 → $145
Current: $81.76
Upside: +77.35%
Nov 25, 2025
Maintains: Overweight
Price Target: $165 → $180
Current: $115.62
Upside: +55.68%
Nov 7, 2025
Maintains: Underweight
Price Target: $26 → $22
Current: $12.29
Upside: +79.01%
Nov 7, 2025
Maintains: Neutral
Price Target: $13 → $15
Current: $22.28
Upside: -32.68%
Nov 5, 2025
Maintains: Neutral
Price Target: $14 → $16
Current: $15.81
Upside: +1.20%
Oct 30, 2025
Downgrades: Neutral
Price Target: $14 → $12
Current: $7.97
Upside: +50.56%
Oct 9, 2025
Maintains: Neutral
Price Target: $300 → $325
Current: $299.79
Upside: +8.41%
Oct 9, 2025
Maintains: Overweight
Price Target: $600 → $650
Current: $468.04
Upside: +38.88%
Oct 9, 2025
Maintains: Neutral
Price Target: $1,200 → $1,285
Current: $1,274.70
Upside: +0.81%
Apr 29, 2025
Downgrades: Neutral
Price Target: $265 → $150
Current: $103.21
Upside: +45.33%
May 13, 2024
Maintains: Neutral
Price Target: $7 → $6
Current: $3.01
Upside: +99.34%
Oct 31, 2023
Maintains: Neutral
Price Target: $25 → $23
Current: $26.32
Upside: -12.61%